Nippon Shinyaku has a total of 1870 patents globally, out of which 780 have been granted. Of these 1870 patents, more than 56% patents are active. Japan is where Nippon Shinyaku has filed the maximum number of patents, followed by United States of America and Europe. Parallelly, Japan seems to be the main focused R&D centre and also is the origin country of Nippon Shinyaku.
Nippon Shinyaku was founded in the year 1911. The Company manufactures pharmaceutical and health foods products. The Company produces drugs for urinary, nerve, respiratory and circulatory systems as well as analgesic and anti-inflammatory drugs. Nippon Shinyaku also develops synthetic anti-bacterial agents. As of March 2023, the market cap of Nippon Shinyaku is $3.03 Billion.
Do read about some of the most popular patents of Nippon Shinyaku which have been covered by us in this article and also you can find Nippon Shinyaku patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Nippon Shinyaku patent portfolio.
How many patents does the founder of Nippon Shinyaku have?
The founder Hisomu Ichinose has 1 patent
How many patents does Nippon Shinyaku have?
Nippon Shinyaku has a total of 1870 patents globally. These patents belong to 422 unique patent families. Out of 1870 patents, 1057 patents are active.
How Many Patents did Nippon Shinyaku File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Nippon Shinyaku Applications Filed | Nippon Shinyaku Patents Granted |
| 2023 | 1 | 5 |
| 2022 | 71 | 32 |
| 2021 | 66 | 60 |
| 2020 | 170 | 85 |
| 2019 | 125 | 47 |
| 2018 | 85 | 33 |
| 2017 | 52 | 63 |
| 2016 | 86 | 55 |
| 2015 | 116 | 28 |
| 2014 | 26 | 39 |
| 2013 | 42 | 46 |
| 2012 | 55 | 40 |
Which Nippon Shinyaku Drug Patents are Expiring in the Next 10 Years?
The patent no. US9079934B2 which is expiring in Aug, 2031, describing invention that offers an oligomer that effectively induces the skipping of the 53rd exon in the human dystrophin gene. Additionally, a pharmaceutical composition with high efficiency in causing this exon skipping is provided.
Given below is the list of few drugs patented by Nippon Shinyaku accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.
| Drug Name | Patent Number | Patent Title | Patent Expiration |
| Viltepso | US9079934B2 | Antisense nucleic acids | Aug, 2031 |
Interested in knowing about Nippon Shinyaku’s Drug Patents Expiring in the next 10 years?
How many Nippon Shinyaku patents are Alive/Dead?
How Many Patents did Nippon Shinyaku File in Different Countries?
Countries in which Nippon Shinyaku Filed Patents
| Country | Patents |
| Japan | 258 |
| United States Of America | 145 |
| Europe | 129 |
| China | 97 |
| Korea (South) | 93 |
| Canada | 77 |
| Australia | 73 |
| India | 58 |
| Germany | 56 |
| Mexico | 51 |
| Brazil | 49 |
| Russia | 49 |
| Taiwan | 44 |
| Spain | 31 |
| Hong Kong (S.A.R.) | 28 |
| South Africa | 27 |
| Indonesia | 27 |
| Viet Nam | 27 |
| Philippines | 26 |
| Israel | 25 |
| Denmark | 24 |
| Portugal | 23 |
| Austria | 21 |
| Hungary | 19 |
| Malaysia | 19 |
| Singapore | 19 |
| Norway | 19 |
| Colombia | 19 |
| Poland | 18 |
| Slovenia | 17 |
Where are Research Centres of Nippon Shinyaku Patents Located?
10 Best Nippon Shinyaku Patents
WO2002088084A1 is the most popular patent in the Nippon Shinyaku portfolio. It has received 170 citations so far from companies like Toray Industries, Cardio and Sandoz.
Below is the list of 10 most cited patents of Nippon Shinyaku:
| Publication Number | Citation Count |
| WO2002088084A1 | 170 |
| WO2012029986A1 | 165 |
| WO2013100190A1 | 137 |
| WO2012043730A1 | 128 |
| WO2006022323A1 | 80 |
| WO2004002963A1 | 80 |
| WO2009157398A1 | 60 |
| US7205302B2 | 59 |
| WO2010090290A1 | 59 |
| WO2003037862A1 | 58 |
How many inventions of other companies were rejected due to Nippon Shinyaku patents?
The statistics below share strategic R&D insights. It tells the companies that were trying to protect inventions similar to Nippon Shinyaku invention. They couldn’t because Nippon Shinyaku had protected those before them.
Examiners at the USPTO referred 22 Nippon Shinyaku patents in 79 rejections (35 USC § 102 or 35 USC § 103 types).
The top citing companies in the Nippon Shinyaku patent portfolio are Sarepta Therapeutics, Belrose Pharma and Biomarin Technologies.
List of the Companies whose Patents were rejected citing Nippon Shinyaku –
| Company | Number of Patent Applications that faced Rejection Citing Nippon Shinyaku Patents | Number of Rejections (102 & 103) |
| Sarepta Therapeutics | 8 | 16 |
| Belrose Pharma | 2 | 5 |
| Biomarin Technologies | 2 | 3 |
| Biorelevantcom | 2 | 3 |
| Academisch Ziekenhuis Leiden | 1 | 1 |
| Snu R&Db Foundation | 1 | 1 |
| Mizkan Holdings | 1 | 2 |
| Bend Research | 1 | 2 |
| Toray Industries | 1 | 2 |
| Bio Ved Pharmaceuticals | 1 | 1 |
Count of 102 and 103 Type Rejections based on Nippon Shinyaku Patents
Top Nippon Shinyaku Patents used in Rejecting Most Patent Applications
| Patent Number | Count of Rejected Applications |
| US9079934B2 | 9 |
| US6537561B1 | 5 |
| US9512424B2 | 3 |
| US6468565B1 | 3 |
| US20080020990A1 | 2 |
| US7205302B2 | 2 |
| US20130225548A1 | 2 |
| US20090137790A1 | 1 |
| US6994283B1 | 1 |
| US20060166315A1 | 1 |
| US7198803B2 | 1 |
| US7144906B2 | 1 |
| US20070190081A1 | 1 |
| US8282956B2 | 1 |
| US7728131B2 | 1 |